Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

Trial Details

NCT ID
NCT06508463
Phase
PHASE1
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Bone Marrow Biopsy
  • Computed Tomography
  • Positron Emission Tomography
  • Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Age \>= 18 years
  • Relapsed or refractory:
  • Group E only: Relapsed peripheral T-cell lymphoma (PTCL) of the following histologies: peripheral T-cell lymphoma-NOS (PTCL-NOS); anaplastic large …
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2 times upper limit of normal (ULN) (obtained =\< 15 days prior to registra…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →